drugset / Trial / NCT06150014
A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required
Timeline
- Start
- 2023-12-07
- Primary completion
- 2025-12
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TQA3605 | Unknown | 50 mg | Oral |
| Comparator | TQA3605 | Unknown | 100 mg | Oral |
| Comparator | TQA3605 | Unknown | 200 mg | Oral |
| Comparator | TQA3605 | Unknown | 300 mg | Oral |
| Comparator | Entecavir | Small molecule | — | Oral |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | Oral |
| Comparator | tenofovir alafenamide | Small molecule | — | Oral |